Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2023-10-20 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
关于子公司与ATHENEX,INC.合作事项进展暨子公司回购股份的公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the progress of cooperation with ATHENEX, INC. and a share repurchase transaction involving subsidiaries and related parties. It includes background information, transaction details, financial data of involved entities, agreement terms, independent director opinions, impact analysis, and risk disclosures. The content focuses on a specific capital transaction (share repurchase) and related corporate agreements rather than a general financial report, earnings release, or management discussion. It is not a full annual or interim report, nor a regulatory filing or legal proceeding update. The document is comprehensive and exceeds 5,000 characters, indicating it is not merely an announcement of a report publication. The primary subject is the share repurchase transaction and cooperation progress, fitting the category of Transaction in Own Shares (POS).
2023-10-20 Chinese
第九届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 15th meeting of the 9th Board of Directors of Guangzhou Xiangxue Pharmaceutical Co., Ltd. It details board decisions including approval of a subsidiary's cooperation and share repurchase agreement, and the scheduling of an extraordinary general meeting. The content focuses on board meeting resolutions and procedural matters rather than full financial reports or earnings data. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or voting results announcement. The document fits the category of Board/Management Information (MANG) as it announces board meeting decisions and related corporate governance actions.
2023-10-20 Chinese
关于持股5%以上股东所持部分股份被司法冻结的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the judicial freezing of shares held by a major shareholder (Kunlun Investment). It details the number of shares frozen, the proportion of total shares, and the impact on the company. There is no financial data, no report attached or referenced as being published, and no mention of financial results or management changes. This is a regulatory announcement about shareholding status and legal restrictions on shares, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories like Major Shareholding Notification (MRQ) because it concerns judicial freezing rather than ownership threshold changes, nor is it a Director's Dealing or Capital/Financing Update. The document is short (1313 characters) and is a formal disclosure of a legal event affecting shares.
2023-10-11 Chinese
关于公司及子公司新增被申请强制执行的公告
Legal Proceedings Report Classification · 95% confidence The document is an announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding new forced execution applications against the company and its subsidiaries. It details legal enforcement actions, case numbers, involved parties, and the company's response and risk mitigation measures. There are no financial statements, earnings data, or detailed financial analysis present. The document is a regulatory announcement about legal proceedings and enforcement actions, not a financial report or earnings release. It fits best under Legal Proceedings Report (LTR) as it updates on significant lawsuits and regulatory actions involving the company.
2023-09-28 Chinese
关于参加2023广东辖区上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an investor online collective reception day event organized by regulatory bodies. It mentions interaction with investors regarding the company's 2023 half-year operating results, governance, strategy, and business conditions. The document is short (671 characters) and serves as a notice of an upcoming event rather than containing actual financial data or detailed reports. It does not contain financial statements or substantive financial analysis, so it is not an Interim/Quarterly Report (IR) or Annual Report (10-K). It is also not a call transcript (CT) since it is a notice of a future event. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about investor relations activities and does not fit other specific categories.
2023-09-18 Chinese
关于控股股东提前终止减持计划的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the early termination of a share reduction plan by the controlling shareholder. It references a previous disclosure about a share reduction plan and states that the controlling shareholder has decided to terminate the plan early. There is no financial data, no report attached or referenced as being published, and no mention of management changes, dividends, or other report types. This fits the category of a Share Issue/Capital Change announcement, specifically about shareholding changes by a major shareholder or controlling shareholder's share reduction plan. Therefore, the appropriate classification is SHA (Share Issue/Capital Change). The document length is short and it is a direct announcement, not a report or regulatory filing. Confidence is high due to clear content and context.
2023-08-29 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.